Hormonothrapie cancer de la prostate pdf

Sa seule utilisation dans le cancer de la prostate est le guidage des biopsies. De plus en plus, linterprtation inclut diffrentes squences dont la squence T2, la diffusion, la restriction ou lhypervascularisation prenant le nom dIRM multiparamtrique.

Actuellement, elle est recommande selon lAFU dans les cancers de prostate de risque intermdiaire et lev pour valuer le sige des tumeurs, linfiltration ou le franchissement de la capsule et lenvahissement des vsicules sminales.

Enfin, lIRM peut mettre en vidence des adnopathies suspectes pelviennes ou des lsions osseuses des os du pelvis. Il peut mettre en vidence des adnopathies pelviennes et rtropritonales ou des lsions osseuses ostocondensantes. Il peut aussi mettre en vidence dautres pathologies tumorales. Sa limite reste sa faible spcificit. Elle doit tre ralise dans le cadre du cancer de prostate de risque intermdiaire et haut risque DAmico. Elle reste infrieure la scintigraphie osseuse pour le diagnostic ou le suivi des mtastases osseuses.

Le PET-Scan nest pas recommand actuellement. Classification TNM grade histopronostique 4. Celui-ci se dveloppe prfrentiellement dans la partie priphrique de la prostate par opposition la zone de transition o se dveloppe lhyperplasie bnigne. Le carcinome neuroendocrine est trs rare, et la forme de sarcome prostatique est exceptionnelle. Le score de Gleason est un score histopronostique caractrisant le degr de diffrenciation de la tumeur, et un facteur pronostique essentiel dans la prise en charge du cancer de prostate.

Il coexiste en fait au sein de la glande prostatique plusieurs foyers tumoraux dvolution diffrente et des stades de diffrenciations pouvant tre diffrents figures 3 - 4 - 5. Le score de Gleason est obtenu en additionnant les 2 grades histologiques allant de 1 5, des cancers les plus reprsents.

Score de 6 : cancer de la prostate bien diffrenci et de bon pronostic exceptionnellement il est. Les scores infrieurs ont t abandonns. Score de 8 10 : cancer de la prostate peu diffrenci, de mauvais pronostic. Ce score est donc bas sur laspect des glandes au sein de la tumeur. Figure 3 : Aspect de glande prostatique selon sa diffrenciation.

Source : Annales de Pathologie, vol. Elsevier Masson SAS. Les marges aprs prostatectomie sont codes comme suit : Rx : non valu R0 : Absence de reliquat tumoral macroscopique ou microscopique R1 : Reliquat microscopique focal ou tendu prciser.

Il est alors prcis sur le compte rendu. Traitements La dcision dun traitement ou dune prise en charge du cancer de la prostate passe obligatoirement par une discussion au cours des runions de concertation pluridisciplinaire runissant urologues, oncologues, radiothrapeutes, radiologues, anatomopathologistes et onco-griatres.

Options thrapeutiques 1 Surveillance active Le principe est bas sur le fait que beaucoup de cancers de la prostate de score de Gleason 6 ou de faible risque de progression selon DAmico ne vont pas progresser ou voluer lentement sans avoir un impact sur la survie du patient. Lindication de la surveillance active est donc un cancer de prostate cliniquement localis et faible risque de progression pour des patients dont lesprance de vie est suprieure 10 ans. Le critre darrt de la surveillance est un temps rapide de doublement du PSA ou lapparition de cancer de grade de Gleason 4 ou 5 sur les biopsies rptes.

Elle comporte : lexrse complte de la prostate et des vsicules sminales lanastomose vsico-urtrale. Elle peut sassocier dun curage ilio-obturateur bilatral, voire dun curage extensif du pelvis pour les cancers de prostate localiss risque intermdiaire ou haut risque. Il existe plusieurs voies dabord chirurgicales : voie ouverte rtropubienne, prinale, laparoscopique ou laparoscopique assiste par robot figure 7.

Aucune voie dabord na fait preuve dune supriorit par rapport une autre en termes de contrle carcinologique. Figure 7 : Intervention par chirurgie robot assist. Source : E. Xylinas, L. Salomon, C. Abbou, A.

Prostatectomie radicale extrapritonale coelioscopique robot-assiste : technique chirurgicale, rsultats oncologiques et fonctionnels. Les effets secondaires de la chirurgie sont : incontinence urinaire : frquente aprs lintervention chirurgicale, elle rgresse dans les semaines. Il convient dajouter les risques lis lanesthsie, de saignement, de transfusion, dinfection et de lsions des organes avoisinants exceptionnelles. Recommandation AFU Le curage ganglionnaire tendu doit tre effectu en cas de risque intermdiaire ou lev si le choix du traitement est la prostatectomie totale.

Il sagit aussi dun traitement curateur. Elle est aujourdhui utilise selon une technique conformationnelle tridimensionnelle, et a pour but de diminuer les effets secondaires lis lirradiation des organes adjacents. Les patients peuvent cependant se plaindre de :. Les contre-indications regroupent les antcdents d'irradiation plevienne antrieure ou de maladie inflammatoire rectale. La radiothrapie peut tre associe une hormonothrapie de courte dure de 6 mois pour les cancers risque intermdiaire ou de longue dure de 3 ans pour les cancers haut risque de progression.

Le plus souvent, il sagit de limplantation de grains diode I Figure 8 : Aspect postcuriethrapie. Lindication ce jour de la curiethrapie est essentiellement pour les patients atteints dun cancer de prostate localis et de faible risque DAmico ayant une esprance de vie de plus de 10 ans.

Les risques sont les mmes que ceux de lirradiation externe. Lindication idale est le traitement des cancers rcidivants localement aprs radiothrapie. Les risques sont les risques lis lanesthsie, de transfusion, dinfection, de stnose, de fistule urtrorectale ou prostato-rectale, dincontinence et de troubles de lrection. La cryothrapie a pour seule indication la rcidive locale aprs radiothrapie.

Peu de centres en France lutilisent. Les risques propres sont les stnoses, lincontinence, les troubles de lrection et la rcidive. La glande prostatique et le cancer de la prostate sont lis la prsence de testostrone, et labsence de cette dernire entrane une apoptose massive des cellules. Dans le cas des cellules tumorales, un contingent est capable de survivre et de se dvelopper en labsence dandrognes et va tre responsable de lvolution pjorative.

Le blocage andrognique a pour but la suppression de leffet des andrognes par suppression de leur production, associe ou non un blocage des rcepteurs priphriques aux andrognes. Son efficacit vaut pendant la priode transitoire pouvant aller de quelques mois plusieurs annes. En moyenne chez le patient mtastatique, lefficacit est de 3 ans. Elle est donc palliative. La suppression andrognique peut tre : chirurgicale par la ralisation dune pulpectomie bilatrale.

Elle est alors dfinitive ; ou mdicale hormonothrapie. Lhormonothrapie mdicale utilise les approches suivantes : les agonistes de la LHRH : ces traitements ont pour but de saturer la voie de la LHRH aboutissant. Il existe un effet rebond linduction du traitement entranant une lvation brutale de la testostronmie avant son effondrement : cet effet est dit flare up ncessitant une co-prescription dun anti-androgne pendant au moins 1 mois.

Ex : anti-andrognes strodiens : actate de cyprotrone Androcur , anti-andrognes non strodiens : bicatulamide Casodex , nicutamide Anandron. Les traitements sont prescrits en continu ou de faon intermittente.

Les effets secondaires sont nombreux, majoritairement lis la baisse de la testostrone figure 10 :. Classiquement, une monothrapie par agoniste ou antagoniste est prescrite en premire ligne mais elle associe en cas dagoniste un anti-androgne chez les patients mtastatiques pour prvenir de leffet FLARE UP 10 jours avant et 1 mois aprs.

Cette hormonosensibilit ne dure cependant quun temps. On parle alors de cancer de prostate en phase de rsistance la castration. Il se dfinit selon plusieurs critres selon les recommandations de lAFU :. Son usage est limit devant un risque faible, mais non ngligeable, thrombo-embolique. De la mme manire, on peut utiliser de lestramustine Estracyt raison de 2 gel. La molcule la plus avance est lactate dabiratrone, inhibiteur de la synthse des andrognes, notamment en inhibant le complexe CYP au sein de la surrnale.

Lactate dabiratrone Zytiga a obtenu lAMM en postchimiothrapie et bientt en pr-chimiothrapie galement , aprs avoir prouv dans une phase 3, un gain en survie globale. Dautres molcules sont en cours de validation : lortronel, ayant un effet abiratrone-like ; MDV, dont laction diffre par son ciblage sur les rcepteurs androgniques directement. Les modalits daction des traitements hormonaux du cancer de la prostate sont rsumes dans la figure Le plus difficile est de trouver le bon moment pour initier le traitement.

Actuellement, un patient porteur de mtastases hpatiques ou trs symptomatiques douleur semble tre le bon moment pour employer ce traitement. La molcule de 1re intention est le doctaxel Taxotre associ de la prednisone, molcule appartenant la famille des inhibiteurs des microtubules.

En 2e ligne et pour les malades ayant eu une bonne rponse premire au doctaxel, le cabazitaxel Jevtana est une nouvelle chimiothrapie en cours dobtention dAMM. Il sagit dune taxane semisynthtique ayant montr rcemment une amlioration de la survie globale.

Sa place est dmontre dans le cancer de prostate rsistant la castration et a un effet clinique sur lvnement osseux fracture osseuse, douleur osseuse, hypercalcmie, compression mdullaire. Il est probable que dans les mois venir lalpharadine chlorure de radium remplace lacide zoldronique par une efficacit suprieure sur la rduction de la progression des mtastases osseuses, sur la rduction des vnements osseux types fractures ou tassement, et sur laugmentation de la survie globale.

Deux situations sont donc possibles : soit le volume de la prostate cancreuse obstrue la filire urtrale il sagit alors dun obstacle sous-. Lobjectif du clinicien est le traitement de tout nouveau symptme pouvant entraver le quotidien du patient. La prise en charge se fait de manire pluridisciplinaire et les dcisions sont souvent prises en runion de concertation pluridisciplinaire RCP , notamment avec laide active des quipes de soins palliatifs, du mdecin rfrent et des mdecins algologues.

Stratgie thrapeutique Le choix thrapeutique dpend du stade, de la diffrenciation, des troubles mictionnels ventuels, des facteurs de comorbidits, des signes cliniques prsents au diagnostic et de lesprance de vie du patient. Eur Urol ; Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1, cases.

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. Prostate cancer screening in the randomized Prostate, Lung. Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

J Natl Cancer Inst ; Prostate-cancer mortality at 11 years follow-up. Ann Intern Med ; Dpistage du cancer de la prostate chez les populations dhommes prsentant des facteurs de risque. Cancer de la prostate et dpistage. Screening of prostate cancer decreases the risk of developing metastatic disease: findings of the European Randomized Study of Screening of Prostate Cancer.

Early detection of prostate cancer : European Urology Association of Urology recommendation. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy.

The year Johns Hopkins experience. Urol Clin North Am ; Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology ; Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. Optimal timing, cutoff and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.

Prostate cohort outcomes initiative: Pretreatment PSA, velocity as a predictor of disease outcome following radical radiation therapy. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol ;SS Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.

Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Urinary biomarkers in prostate cancer: an update. Prog Urol ; Implications of the International Society of urological Pathology modified Gleason grading system. Arch Pathol Lab Med ; Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.

The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer ; Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.

Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis.

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.

Place de la surveillance active dans le cancer de la prostate faible risque de progression. Radical prostatectomy versus observation for localized prostate cancer. Radical prostatectomy versus watchful waiting in early prostate cancer. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Active surveillance for the management of prostate cancer in a contemporary cohort. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol Feb A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Place de la surveillance active dans le cancer de prostate: prsentation du protocole franais. Robot-assisted radical prostatectomy compared with open and laparoscopic approaches: A systematic review and meta-analysis.

Int J Urol ; Extrafascial versus interfascial nerve-sparing robotic-assisted laparoscopic radical prostatectomy: comparison of functional outcomes and positive surgical margins characteristics.

Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.

Bilateral vs unilateral laparoscopic intrafascial nervesparing radical prostatectomy: evaluation of surgical and functional outcomes in patients. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol ; Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy.

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy.

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out. Neoadjuvant hormone treatment with leuprolide acetate depot 3. Urol Int ; Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial EORTC trial Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial.

Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev ; The bicalutamide mg early prostate cancer program: findings of the North American trial at 7. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Lancet Oncol ; Role of androgen deprivation therapy for node-positive prostate cancer. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess ; iii-iv. Higher-than-conventional radiation doses in localized prostate cancer treatment: a metaanalysis of randomized, controlled trials.

Long-term failure patterns and survival in a randomized doseescalation trial for prostate cancer. Who dies of disease?. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Whole-pelvis, mini-pelvis or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group trial. Simultaneous integrated boost plan comparison of volumetricmodulated arc therapy and sliding window intensity modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer.

J Appl Clin Med Phys ; Implementing intensity modulated radiotherapy to the prostate bed: dosimetric study and early clinical results.

Med Dosim ; Radiotherapy and short-term androgen deprivation for localized prostate cancer. Association hormonothrapie et radiothrapie dans le cancer de prostate localement avanc. Bull Cancer ; External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: year results of an EORTC randomised study. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.

American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy ; Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.

Curiethrapie prostatique : indications et rsultats. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Natural history of clinically staged low-and intermediaterisk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine monotherapy over 10years.

Radiother Oncol ; Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score prostate cancer treated with permanent prostate brachytherapy. Radiat Oncol Biol Phys ; High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology.

Systematic review of the efficacy and safety of high-intensity focused ultrasound for the primary and salvage treatment of prostate cancer. Multicentric oncologic outcomes of high intensity focused ultrasound for localized prostate cancer in patients.

Eur Urol Apr 30 [Epub ahead of print]. Primary and salvage cryotherapy for prostate cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.

Intermittent androgen suppression for rising PSA level after radiotherapy. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

FinnProstate Group. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised Finn Prostate Study VII: quality of life and adverse effects. TAP22 Investigators Group. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. Intermittent versus continuous androgen deprivation in prostate cancer.

Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation ; Skeletal fractures negatively correlate with overall survival in men with prostate cancer.

Joint Bone Spine ; Abiraterone and increased survival in metastatic prostate cancer. Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: results of the Cancer and Leukemia Group B study Chemotherapy with mitoxantrone plus prednisone and low dose prednisone in patients with hormonally resistant prostate cancer. TAX Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. Addition of estramus-tine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Multiple cycles of intermittent chemotherapy in metastatic androgenindependent prostate cancer. Br J Cancer ; Docetaxel reintroduction in patients with metastatic hormonerefractory, docetaxel-sensitive, prostate cancer: A retrospective multicenter study TRIADE.

BJU International ; Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Incidence and mortality of incidental prostate cancer: a Swedish registerbased study. Incidental carcinoma of the prostate: an analysis of the predictors of progression. Management of stage A prostate cancer with a high probability of progression.

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. An analysis of watchful waiting for clinically localized prostate cancer. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.

An analysis of men with clinically localized prostate cancer who deferred definitive therapy. Early outcomes of active surveillance for localized prostate cancer. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance: does the risk of misclassification vary according to biopsy criteria?.

Pathological outcomes of candidates for active surveillance of prostate cancer. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res ; Contemporary update of prostate cancer staging nomograms Partin Tables for the new millennium.

Indications and contraindications for nerve-sparing radical prostatectomy. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

J Clin Oncol ;27 Natural history of clinically staged low-and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78Gy. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol in press. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy.

Indications de la lymphadnectomie ilio-obturatrice dans le cancer de prostate cliniquement localis. O, Bratell S. Radical prostatectomy versus wachfulle waiting in localized prostate cancer: the Scandinavian prostate cancer group 4 randomized trial.

Marges positives aprs prostatectomie totale : aspects techniques et valeur pronostique. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Preoperative nomogram predicting the year probability of prostate cancerrecurrence after radical prostatectomy.

Prostate cancer radiation dose response: results of the M. Anderson Phase III randomized trial. Randomized trial comparing iridium implant plus externalbeam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. Long-term results of the M. Anderson randomized doseescalation trial for prostate cancer. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial.

Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Intermediate-and high-risk prostate cancer: a plea for high-dose, high-precision intensity-modulated radiotherapy with a modulated duration of androgen deprivation therapy.

A fifteen-year follow-up. Quality of life after radical prostatectomy or watchful waiting. Outcome following active surveillance of men with screendetected prostate cancer.

Results from the Gteborg randomised population-based prostate cancer screening trial. Active surveillance in men with localized prostate cancer: a systematic review. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database.

Prostate ; Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation.

Clinical outcome of intermediate risk prostate cancer treated with iodine monotherapy: The Hotel-Dieu of Quebec experience. Cancer Radiother ; Long-term biochemical and survival outcome of patients treated with I permanent prostate brachytherapy.

Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine monotherapy over 10 years. American Brachytherapy Society ABS recommendations for transperineal permanent brachytherapy of prostate cancer. Modern prostate brachytherapy. Prostate specific antigen results in patients with up to 12 years of observed follow-up. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB Traitement par HIFU du cancer de la prostate : revue de la littrature et indications de traitement.

Multicentric oncologic outcomes of highintensity focused ultrasound for localized prostate cancer in patients. Cryotherapy for localised prostate cancer. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer.

Cryotherapy for prostate cancer: ready for prime time?. Curr Opin Urol ; Focal cryotherapy for clinically unilateral, lowintermediate risk prostate cancer in 73 men with a median follow-up of 3. Duration of androgen suppression in the treatment of prostate cancer.

Ten-year follow-up of radiation therapy oncology group protocol a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

Tumeurs de la prostate haut risque. Digital rectal exam following prostatectomy: is it still necessary with the use of PSA?. Comit de Cancrologie de lAssociation Franaise dUrologie. Recommandations en onco-urologie. Cancer de la prostate. Prostate specific antigen bounce after prostate brachytherapy: review of a confusing phenomen. Int J Rad Oncol Biophy ; The Dilemna of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques.

Curr Radiopharm , in press [9] Blana A. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommandations of the Prostate Cancer Clinical Trials Working Group.

Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.

Changing patterns in competing causes of death in men with prostate cancer: a population based study. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: a practical approach.

Endorectal magnetic resonance imaging at 1. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging ; J Nucl Med ; Scintigraphie osseuse chez les patients prsentant des mtastases en uro-oncologie : revue de la littrature.

Molecular imaging of prostate cancer: PET radiotracers. Comparison of [18 F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. Can whole-body magnetic resonance imaging with diffusionweighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?. Nuklearmedizin ; Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.

Salvage radiation in men after prostate-specific antigen failure and the rsik of death. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

J Clin Onc ; Long-term failure patterns and survival in a randomized doseescalation trial for prostate cancer Who dies of disease?. Prostatectomie de rattrapage aprs radiothrapie externe pour cancer de la prostate : indications, morbidit et rsultats. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.

Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.

Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol Sep 28 [Epub ahead of print]. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy.

Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group Eur Urol , in press [34] Pasticier G.

Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Open navigation menu. Close suggestions Search Search. User Settings. Skip carousel. Carousel Previous. Carousel Next. What is Scribd? Explore Ebooks. Bestsellers Editors' Picks All Ebooks. Explore Audiobooks. Bestsellers Editors' Picks All audiobooks. Explore Magazines. Editors' Picks All magazines. Explore Podcasts All podcasts. Difficulty Beginner Intermediate Advanced.

Explore Documents. Uploaded by Youness Dehayni. BMJ b Download references. Zongo, A. Sanou, G. Bonkoungou, M. Zida, D. You can also search for this author in PubMed Google Scholar. Correspondence to N. Zongo, N. J Afr Cancer 3, 40—43 Download citation. Received : 12 February Accepted : 15 April Published : 04 December Issue Date : February Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative. Skip to main content.